Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Aljunid, Syed ^a,b   Abuduxike, Gulifeiya ^a   Ahmed, Zafar ^b   Sulong, Saperi ^b   Nur, Amrizal M ^b   Goh, Adrian ^c  

^a UKM Medical Centre   (Malaysia)

^b UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^c Azmi Burhani Consulting ^*  (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE;

ADULT; AGED; ARTICLE; BACTERIAL LOAD; CHILD HEALTH CARE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; HEALTH PROGRAM; HERD IMMUNITY; HUMAN; INFANT; INFECTION PREVENTION; MALAYSIA; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; SENSITIVITY ANALYSIS; VACCINATION; ADOLESCENT; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE COST; IMMUNOLOGY; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; NEWBORN; PRESCHOOL CHILD; STATISTICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; INFANT; INFANT, NEWBORN; MALAYSIA; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINATION; YOUNG ADULT;

EID: 80053172303     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-248     Document Type: Article

References (41)

1. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000, 30:100-121. 10.1086/313608, 10619740.
2. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010, 14:e197-209.
3. Lin TY, Shah NK, Brooks D, Garcia CS. Summary of invasive pneumococcal disease burden among children in the Asia-Pacific region. Vaccine 2010, 28:7589-7605. 10.1016/j.vaccine.2010.07.053, 20674872.
4. Gil-Prieto R, García-García L, Alvaro-Meca A, Méndez C, García A, de Miguel AG. The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003-2007). Vaccine 2011, (29):412-416.
5. Centers for Disease Control and Prevention Epidemiology and Prevention of Vaccine-Preventable Diseases. 2011, Washington DC: Public Health Foundation, 12, Centers for Disease Control and Prevention.
6. World Health Organization Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Record 2007, 82:93-104. World Health Organization.
7. Pneumococcal Disease Working Group PneumoAware 2010. Pneumococcal Disease Working Group., http://www.pneumo.co.uk/Portals/0/Reports/Burden_of_Disease_England_Pneumoaware_Report.pdf
8. Jover F, Cuadrado JM, Andreu L, Martínez S, Cañizares R, de la Tabla VO, Martin C, Roig P, Merino J. A comparative study of bacteremic and non-bacteremic pneumococcal pneumonia. Eur J Intern Med 2008, 19:15-21. 10.1016/j.ejim.2007.03.015, 18206596.
9. World Health Organization Pneumococcal vaccines. Wkly Epidemiol Record 2003, 14:110-19. World Health Organization.
10. Levine OS, O'Brien KL, Knoll M, Adegbola RA, Black S, Cherian T, Dagan R, Goldblatt D, Grange A, Greenwood B, Hennessy T, Klugman KP, Madhi SA, Mulholland K, Nohynek H, Santosham M, Saha SK, Scott JA, Sow S, Whitney CG, Cutts F. Pneumococcal vaccination in developing countries. Lancet 2006, 367(9526):1880-1882. 10.1016/S0140-6736(06)68703-5, 16765742.
11. Centers for Disease Control and Prevention Vaccine preventable deaths and the global immunization vision and strategy, 2006-2015. MMWR Morb Mortal Wkly Rep 2006, 55:511-515. Centers for Disease Control and Prevention.
12. Ministry of Health Malaysia Health Facts 2009. 2010, Ministry of Health Malaysia., http://www.moh.gov.my/images/gallery/stats/heal_fact/healthfact-P_2009.pdf
13. Prevenar Malaysian Package Insert. 2006,
14. Levine OS, Knoll MD, Jones A, Walker DG, Risko N, Gilani Z. Global status of Haemophilus influenzae type b and pneumococcal conjugate vaccines: evidence, policies, and introductions. Curr Opin Infect Dis 2010, (23):236-241.
15. John TJ, Samuel R. Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol 2000, 16:601-606. 10.1023/A:1007626510002, 11078115.
16. Fox JP, Elveback L, Scott W, Gatewood L, Ackerman E. Herd Immunity: basic concept and relevance to public health immunization practices. Am J Epidemiol 1971, 94:179-189.
17. Plotkin S, Fine P, Eames K, Heyman DL. "Herd Immunity":A Rough Guide. Clin Infect Dis 2001, 52:911-916.
18. O'Brien KL, Dagan R. The potential Indirect effect of conjugate pneumococcal vaccine. Vaccine 2003, 21:1815-1825. 10.1016/S0264-410X(02)00807-1, 12706665.
19. Centers for Disease Control and Prevention Direct and Indirect Effects of Routine Vaccination of Children with 7-Valent Pneumococcal Conjugate Vaccine on Incidence of Invasive Pneumococcal Disease --- United States, 1998--2003. MMWR Morb Mortal Wkly Rep 2005, 54:893-897. Centers for Disease Control and Prevention.
20. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG, . Active Bacterial Core Surveillance Team Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294:2043-2051. 10.1001/jama.294.16.2043, 16249418, Active Bacterial Core Surveillance Team.
21. Metlay JP, Fishman NO, Joffe M, Edelstein PH. Impact of pediatric vaccination with pneumoccal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine 2006, 24:468-475. 10.1016/j.vaccine.2005.07.095, 16125826.
22. McIntosh ED, Conway P, Willingham J, Lloyd A. The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine. Vaccine 2003, 21:2564-2572. 10.1016/S0264-410X(03)00031-8, 12744892.
23. Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ 2008, 86:408-416. 10.2471/BLT.07.048769, 2647437, 18545744.
24. Marcos MA, Martínez E, Almela M, Mensa J, Jiménez de Anta MT. New rapid antigen test for diagnosis of pneumococcal meningitis. Lancet 2001, 12:1499-1500.
25. Department of Statistics Population and housing census statistics of Malaysia 2000 2001, Department of Statistics.
26. Department of Statistics Population distribution by authority areas and mukims. Population and housing census of Malaysia 2000, Department of Statistics.
27. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000, 19:187-195. 10.1097/00006454-200003000-00003, 10749457.
28. Siti Norbaya M, Rohani MY, Nordiah AJ. Antimicrobial susceptibility pattern and serotype distribution among clinical isolates of Streptococcus pneumoniae in Malaysia [poster]. 4th Asian Congress of Pediatric Infectious Disease (ACPID) 2008, Surabaya, Indonesia.
29. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A. Active Bacterial Core Surveillance of the Emerging Infections Program Network: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746. 10.1056/NEJMoa022823, 12724479.
30. World Health Organization Abridged Life Table for Malaysian residents. 2008, World Health Organization., http://apps.who.int/ghodata/?vid = 60990
31. Low S, Chan FL, Cutter J, Ma S, Goh KT, Chew SK. A national study of the epidemiology of pneumococcal disease among hospitalized patients in Singapore: 1995 to 2004. Singapore Med J 2007, 48:824-829.
32. Census and Statistics Department of Hong Kong Death Statistics Census and Statistics Department of Hong Kong., http://www.statistics.gov.hk/stat_table/population/D5320184BXXXXXXXXB.xls
33. World Health Organization Making choices in health: WHO guide to cost-effectiveness analysis 2003, Geneva: World Health Organization, World Health Organization.
34. International Monetary Fund World Economic Outlook Database 2010, International Monetary Fund., http://www.imf.org/external/pubs/ft/weo/2010/02/weodata/index.aspx
35. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495-1502. 10.1016/S0140-6736(06)69637-2, 17071283.
36. Rückinger S, van der Linden M, Reinert RR, von Kries R. Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: An analysis using the indirect cohort method. Vaccine 2010, 28:5012-5016. 10.1016/j.vaccine.2010.05.021, 20546832.
37. Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 2008, 121:253-260. 10.1542/peds.2007-0619, 18245415.
38. World Health Organization Cost-effectiveness Threshold Values World Health Organization., http://www.who.int/choice/costs/CER_thresholds/en/index.html
39. Hooi LS, Lim TO, Goh A, Wong HS, Tan CC, Ahmad G, Morad Z. Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia. Nephrology 2005, 10:25-32. 10.1111/j.1440-1797.2005.00360.x, 15705178.
40. Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V. Impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clinical Therapeutics 2008, 30(8):341-357.
41. Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Mitchel E, Schaffner W, Craig AS, Edwards KM, Griffin MR. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2004, 39:641-648. 10.1086/422653, 15356776.